STIM2

Across TCGA pan-cancer cohorts, STIM2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated STIM2 data layer compared with 29 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher STIM2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated STIM2 expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.

GBM, HNSC, and CCRCC are the cancer types where STIM2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	OS	Tertile	All	0.682	0.336	.002	14	view →
HNSC	OS	Quartile	IV	0.595	0.884	.011	7	view →
CCRCC	DFS	Median	II,III,IV	0.746	0.947	.019	4	view →
LSCC	DFS	Quartile	All	0.546	1.000	.040	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

STIM2–GBM (OS)

Open the GBM breakdown →